Protalix BioTherapeutics, Inc. (PLX) is a small-cap biopharmaceutical company traded on the NYSE American. It develops and commercializes recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system, anchored by two approved rare-disease treatments — Elelyso for Gaucher disease and Elfabrio for Fabry disease. The stock's average analyst price target sits far above the current share price, raising a straightforward question: can PLX reach $11?
Two current, credible price targets were identified for PLX. H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating with a $12 target in September 2026, citing Elfabrio momentum and pipeline upside. A second analyst, reflected in S&P Global polling data, carries a $10 target. The low-to-high range is therefore $10 to $12, and the arithmetic mean of these two figures is $11.00, which rounds to the $11 central target used here.
This is not an official published consensus; it is a calculated average of the verified individual targets. The thinness of coverage matters as much as the number itself. With only two tracked targets and no Hold or Sell ratings in the current dataset, the range is unusually narrow, and it does not capture the kind of debate seen in more widely followed large-cap names. Investors should treat the $11 figure as a directional benchmark rather than a statistically robust "analyst consensus."
PLX shares closed near $2.57 in early November 2026, within a 52-week range of roughly $1.65 to $3.19. The company's market capitalization is approximately $207 million. Reaching the $11 central target would require a gain of about 328% from current levels — by any standard, a very large move.
The path toward such a target would likely depend less on day-to-day trading and more on fundamental inflection points. Protalix has begun generating meaningful net income and positive free cash flow in recent periods, with trailing twelve-month revenue around $80 million. A sustained transition from clinical-stage unpredictability toward reliable, growing commercial revenue would be the central requirement for the market to re-rate the stock toward the higher end of analyst expectations.
From a technical standpoint, PLX has been building a base between roughly $1.65 and $3.19 over the past year. The $3.19 level represents the recent high and a key resistance level that the stock has not yet sustained a break above. A durable move through that zone would signal a potential structural shift, while the $1.65 area marks major support. Because the $11 target sits far beyond any recent traded range, technical analysis offers limited guidance on the path — the move would have to be driven by fundamental re-rating rather than momentum within the current range.
Analyst price targets generally reflect a roughly 12-month research horizon, though no uniform timeline is guaranteed and firms may differ in their assumptions. For PLX, the most relevant upcoming items include quarterly earnings reports, guidance on Elfabrio sales, the European regulatory process for the new dosing regimen, and any updates on the PRX-115 gout program. Analysts will also watch gross margins, cash levels, and the sustainability of profitability as the key drivers of any re-rating.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For investors tracking a volatile, thinly covered name like PLX, automated signal tools can add a layer of discipline to the decision-making process.
The $11 central target for Protalix BioTherapeutics (PLX) is the average of two verified analyst targets ranging from $10 to $12, and it implies a gain of more than 300% from current levels — a very large move. The constructive case rests on Elfabrio's commercial trajectory, a favorable European regulatory development, improving profitability, and longer-term pipeline optionality. The principal obstacles are partner concentration, quarterly revenue variability, binary clinical outcomes, and a market cap too small to attract broad institutional attention. With such thin analyst coverage and a target well outside the recent trading range, the $11 figure is best understood as a best-case valuation scenario rather than a near-term expectation. Investors should monitor Elfabrio sales, regulatory decisions, and PRX-115 data as the key signposts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PLX has been loosely correlated with ABEO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if PLX jumps, then ABEO could also see price increases.
| Ticker / NAME | Correlation To PLX | 1D Price Change % | ||
|---|---|---|---|---|
| PLX | 100% | +11.28% | ||
| ABEO - PLX | 38% Loosely correlated | -3.35% | ||
| IOVA - PLX | 37% Loosely correlated | -1.10% | ||
| CTMX - PLX | 35% Loosely correlated | N/A | ||
| STOK - PLX | 31% Poorly correlated | -1.80% | ||
| SNDX - PLX | 31% Poorly correlated | -0.63% | ||
More | ||||